MedTrace Logo

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

NCT01009905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22960

Last updated 2017-04-12

No results posted yet for this study

Summary

This study is conducted in the United States of America (USA). The aim of this observational study is to collect data concerning the treatment outcomes and safety for children and adults who are prescribed Norditropin®. Specific objectives include: 1) developing models defining the relationship of Norditropin dose to changes in insulin-like growth factor (IGF-I) and treatment outcomes, accounting for independent factors such as age, gender and puberty and 2) determining the relative predictive values of peak growth hormone (GH) and IGF-I levels and other factors before treatment to clinical outcomes.

Conditions

  • Growth Hormone Disorder
  • Pituitary Dwarfism
  • Hypopituitarism

Interventions

DRUG

somatropin

Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452), MD · Novo Nordisk A/S

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-24
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01009905 on ClinicalTrials.gov